M Holdings Securities Inc. Lowers Holdings in Novo Nordisk A/S (NYSE:NVO)

M Holdings Securities Inc. trimmed its holdings in Novo Nordisk A/S (NYSE:NVO – Get Rating) by 6.7% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 2,285 shares of the company’s stock after selling 165 shares during the period. M Holdings Securities Inc.’s holdings in Novo Nordisk A/S were worth $228,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the business. Advisors Capital Management LLC grew its position in Novo Nordisk A/S by 91.3% in the third quarter. Advisors Capital Management LLC now owns 3,939 shares of the company’s stock worth $451,000 after acquiring an additional 1,880 shares during the period. Kayne Anderson Rudnick Investment Management LLC purchased a new position in Novo Nordisk A/S in the third quarter worth approximately $1,686,000. Captrust Financial Advisors grew its position in Novo Nordisk A/S by 24.4% in the third quarter. Captrust Financial Advisors now owns 31,971 shares of the company’s stock worth $3,185,000 after acquiring an additional 6,277 shares during the period. Wealth Advisory Solutions LLC purchased a new position in Novo Nordisk A/S in the third quarter worth approximately $3,172,000. Finally, Advisory Research Inc. grew its position in Novo Nordisk A/S by 58.9% in the third quarter. Advisory Research Inc. now owns 3,913 shares of the company’s stock worth $390,000 after acquiring an additional 1,451 shares during the period. 6.09% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Trading Down 1.4 %

NYSE:NVO opened at $140.98 on Thursday. The firm has a market cap of $319.03 billion, a PE ratio of 40.63, a price-to-earnings-growth ratio of 1.49 and a beta of 0.47. The stock has a fifty day moving average price of $139.90 and a 200 day moving average price of $123.12. Novo Nordisk A/S has a 12-month low of $95.02 and a 12-month high of $145.94. The company has a current ratio of 0.89, a quick ratio of 0.69 and a debt-to-equity ratio of 0.29.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Tuesday, April 4th. Shareholders of record on Monday, March 27th will be paid a $1.1887 dividend. The ex-dividend date of this dividend is Friday, March 24th. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.58. This represents a yield of 0.8%. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 23.34%.

Analyst Ratings Changes

Several research analysts have recently commented on the company. JPMorgan Chase & Co. raised their price target on Novo Nordisk A/S from 925.00 to 1,100.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 3rd. Cowen raised their price target on Novo Nordisk A/S from $130.00 to $145.00 in a research report on Monday, December 12th. Finally, Cowen raised their price target on Novo Nordisk A/S from $130.00 to $145.00 in a research report on Monday, December 12th. One analyst has rated the stock with a sell rating, four have issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $697.78.

About Novo Nordisk A/S

(Get Rating)

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases.